BSX

BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.

In the most recent trading session, Boston Scientific (BSX) closed at $46.95, indicating a -2.94% shift from the previous trading day.

Boston Scientific faces a cyberattack, weaker 2026 guidance and business pressures, raising concerns over its outlook and whether investors should exit.

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?

AU, APTV and BSX have been added to the Zacks Rank #5 (Strong Sell) List on August 28th, 2026.

Boston Scientific's stock is sliding in the wake of a major cyberattack, adding to its recent woes.

A cyberattack on U.S. medical device maker Boston Scientific is causing an ongoing “global disruption” to its operations, according to a federal regulatory filing on Wednesday, the latest healthtech giant to face a cyberattack in recent weeks.

Boston Scientific was hit with a cyberattack that is affecting its operations, the company said Wednesday in an SEC filing. The attack is continuing to disrupt the company's ability to ship products, and it's not clear when services will be restored.

Boston Scientific said on Wednesday that a cybersecurity incident had disrupted global operations, ​including some information systems used to ‌process and ship customer orders.

Boston Scientific has corrected sharply due to EP and WATCHMAN slowdowns, but 74% of its portfolio continues healthy growth. Weakness in BSX's EP business appears addressable with new product launches like FARAWAVE Ultra and ICE, expected to drive recovery from 2H 2027 onward. Valuation is compelling: BSX trades at 15.27x forward earnings, a significant discount to peers and historical averages, despite resilient core businesses.